Effectiveness of Prophylactic Doses of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery: A Systematic Review and Meta-Analysis

Postoperative bleeding is a major complication in bariatric surgery, contributing to increased morbidity, longer hospital stays, and healthcare costs. Tranexamic acid (TXA), an antifibrinolytic agent, has shown promise in reducing surgical blood loss in various specialties. However, there is still no consensus regarding its effectiveness and safety in bariatric surgery. We performed a systematic review and meta-analysis to evaluate the impact of prophylactic TXA on hemoglobin levels, procedural duration, and hospital length of stay in bariatric surgery patients. PubMed, Embase, and Cochrane Central were searched for randomized controlled trials (RCTs) and observational studies comparing TXA and non-TXA groups in bariatric surgery up to November 2024. Data were independently extracted by two reviewers, and risk of bias was assessed using ROBINS-I and RoB-2. Outcomes were assessed using random-effects models, with heterogeneity evaluated by I2 statistics. Sensitivity analyses and publication bias assessments were also performed. Nine studies (2 RCTs and 7 observational studies) involving 1,956 patients were included. TXA significantly improved hemoglobin levels (MD 0.46 g/dL; 95% CI 0.08-0.84; P = 0.02), reduced procedure duration (MD -9.70 min; 95% CI -14.79 to -4.61; P < 0.01), and shortened hospital length of stay (MD -0.19 days; 95% CI -0.31 to -0.07; P < 0.01). No significant increase in thrombotic events was observed. Sensitivity analyses confirmed the robustness of these findings despite high heterogeneity. Prophylactic TXA may significantly reduce perioperative bleeding (smaller hemoglobin decline), operative time, and length of hospital stay in bariatric surgery, without a signal of increasing thrombotic risks, but this should be interpreted with caution given small sample sizes and low event rates. These results support the integration of TXA into perioperative care protocols for bariatric surgery, offering potential benefits in patient outcomes and surgical efficiency.

Authors

Institutions

Publication Details

Journal
Obesity Surgery
Published
2026-02-21
DOI
https://doi.org/10.1007/s11695-026-08522-7
Primary Topic
Blood transfusion and management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of Prophylactic Doses of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery: A Systematic Review and Meta-Analysis

Josélio Rodrigues de Oliveira Filho, Pedro Bicudo Bregion, Victor Kenzo Ivano, Everton Cazzo
Obesity Surgery
Blood transfusion and management
article

Effectiveness of Prophylactic Doses of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery: A Systematic Review and Meta-Analysis

Josélio Rodrigues de Oliveira Filho, Pedro Bicudo Bregion, Victor Kenzo Ivano, Everton Cazzo
article en

Abstract

Postoperative bleeding is a major complication in bariatric surgery, contributing to increased morbidity, longer hospital stays, and healthcare costs. Tranexamic acid (TXA), an antifibrinolytic agent, has shown promise in reducing surgical blood loss in various specialties. However, there is still no consensus regarding its effectiveness and safety in bariatric surgery. We performed a systematic review and meta-analysis to evaluate the impact of prophylactic TXA on hemoglobin levels, procedural duration, and hospital length of stay in bariatric surgery patients. PubMed, Embase, and Cochrane Central were searched for randomized controlled trials (RCTs) and observational studies comparing TXA and non-TXA groups in bariatric surgery up to November 2024. Data were independently extracted by two reviewers, and risk of bias was assessed using ROBINS-I and RoB-2. Outcomes were assessed using random-effects models, with heterogeneity evaluated by I2 statistics. Sensitivity analyses and publication bias assessments were also performed. Nine studies (2 RCTs and 7 observational studies) involving 1,956 patients were included. TXA significantly improved hemoglobin levels (MD 0.46 g/dL; 95% CI 0.08-0.84; P = 0.02), reduced procedure duration (MD -9.70 min; 95% CI -14.79 to -4.61; P < 0.01), and shortened hospital length of stay (MD -0.19 days; 95% CI -0.31 to -0.07; P < 0.01). No significant increase in thrombotic events was observed. Sensitivity analyses confirmed the robustness of these findings despite high heterogeneity. Prophylactic TXA may significantly reduce perioperative bleeding (smaller hemoglobin decline), operative time, and length of hospital stay in bariatric surgery, without a signal of increasing thrombotic risks, but this should be interpreted with caution given small sample sizes and low event rates. These results support the integration of TXA into perioperative care protocols for bariatric surgery, offering potential benefits in patient outcomes and surgical efficiency.

Obesity Surgery
Universidade Estadual de Campinas (UNICAMP) (BR), Massachusetts General Hospital (US)
Good health and well-being
Openalex Percentile: Top 50%
Blood transfusion and management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.